CV: Peter T. Frame MD

Peter T. Frame, MD
Emeritus Professor of Clinical Medicine
Division of Infectious Diseases
Department of Internal Medicine
College of Medicine
University of Cincinnati

Answers questions in the following forums:

Infectious Diseases

Practice Address:

Infectious Disease Center - Holmes Hospital
Eden Ave & Sabin Way
Cincinnati, Ohio 45267-0405

Education:

Princeton University, A.B., University of Cincinnati, M.D.
University of Cincinnati Graduate School, M.A.
University of Cincinnati College of Medicine, M.D.

Post Graduate Training:

1969-1970 Department of Internal Medicine Internship, University of Cincinnati
Department of Internal Medicine Assistant Residency, University of Cincinnati
1973-1974 Department of Internal Medicine Chief Residency, University of Cincinnati
1972-1975 Fellowship: Infectious Diseases, University of Cincinnati

Licensure or Certification:

State Medical Board of Ohio, #031779
Diplomate in Internal Medicine, American Board of Internal Medicine, #38676
Diplomate in Infectious Disease, American Board of Internal Medicine

Associations:

AIDS Clinical Trials Group (ACTG) national Institutes of Health
Infectious Disease Society of America
American College of Physicians
Cincinnati Society of Internal Medicine
American Society of Microbiology
American Federation for Clinical Research

Partial List of Publications:

Stretcher, B.N., Pesce, A.J., Frame, P.T., Greenberg, K.A., Stein, D.S. Correlates of Zidovudine Phosphorylation with Markers of HIV Disease Progression and Druf Toxicity. AIDS. 1994; 8: 763-769.
Chaturvedi, S., Frame, P., Newman, S. Macrophages from Human Immunodeficiency Virus-Positive (HIV)-Positive Persons are Defective in Host Defense Against Histoplasma capsulatum. Journal of Infectious Diseases. 1995; 171: 320-327.
Bozzette, S.A., Finkelstein, D.M., Spector, S.A., Frame, P., Powderly, W.G., He, W., Phillips, L., Craven, D., Van der Horst, C., Feinberg, J. A Randomized Clinical Trial of Three Anti-Pneumocystis Agents in Patients with Advanced HIV Infection. New England Journal of Medicine. 1995; 332: 693-699
Powderly, W.G., Finkelstein, D., Feinberg, J., Frame, P., He, W., Van der Horst, C., Koletar, S.L., Eyster, M.E., Carey, J., Wakin, H., Hooton, T.M., Hyslop, N., Spector, S.A., Bozzette, S.A: A Randomized Clinical Trial of Fluconazole Versus Clotrimazole Troches for the Prevention of Fungal Infections in Patients with Advanced HIV Infection. New England Journal of Medicine. 1995; 332: 700-705.
Montgomery, A.B., Feigal, D.W., Sattler, F., Mason, R., Frame, P.T., et al. Pentamidine Aerosol Versus Trimethoprim-Sulfamethoxazole for Pneumocystis carinii in Acquired Immune Deficiency Syndrome. American Journal of Respiratory Critical Care Medicine. 1995; 151: 1068-1074.
Dohn, M.N. and Frame, P.T. Treatment of Parasitic Diseases (including Pneumocystis carinii). Powderly, WG, ed., Washington Manual of HIV therapeutics (in press).
McKenzie, S., Means, R., Frame, P.T. Serum Chemokine levels in Patients With Non-Progressing Human Immunodeficiency Virus (HIV) Infection. Journal of AIDS. 1996; 10: F29-F33.
Safrin, S., Finkelstein, D.M., Feinberg, J., Frame, P.T., et al. Comparison of Three Regimens for Treatment of Mild to moderate Pneumocystis carinii Pneumonia in patients with AIDS. Annuls of Internal Medicine. 1996;124; 792-802.
Jacobson, M., Fischl, A., Reichman, R., Leedom, J., Sacks, H., Soeiro, R., Powderly, W., Frame, P., et al. A phase II Randomized double-blind Study of Combination with Zidovudine. ACTG. 259.
Theus, S., Sawhney, N., Smulian, G., Walzer, P. Proliferative and Cytokine Responses of Human T Lymphocytes Isolated from HIV Patients to the Major Surface Glycoprotein of Pneumocystis carinii. Submitted.

Hospital Appointments:

1985-present Director, University of Cincinnati AIDS Treatment Center
1981-present Co-director, Infectious Disease Clinic, University of Cincinnati
1975-present Attending Physician, University of Cincinnati Hospitals
1975-present Attending Physician, Veterans Administration Hospital
1975-present Medical consultant, Clinical Microbiology Laboratory, University of Cincinnati Medical Center
1992-present Consulting Staff Physician, Good Samaritan, St. Francis-St. George, Providence Hospitals

Grants:

Principal Investigator: A125897. "Therapy/Basic Studies/Outreach Program in HIV Infection", National Institute of Allergy and Infectious Diseases, 55% effort; annul total costs $1,700,000; project period 01/04/96-12/31/99.
Co-investigator: "Greater Cincinnati Health Care Consortium." A HHS grant to Cincinnati Health Network, Inc. (Bureau of Health Care Delivery Assessment); $476,000, Peter T. Frame; 8% effort; project period 1/94-12/97.
Principal Investigator: "A Double Blind Randomized Comparative Study of Delaviridine Mesylate in Combination with Didanosine (ddl) Versus ddl Alone in HIV Infected Individuals with CD4 Counts < 300/mm^3." Upjohn, project period 3/94-12/96.
Principal Investigator: "A Double Blind Randomized Comparative Study of Delaviridine Mesylate in combination with Didanosine (ddl) versus ddl Alone in HIV Infected Individuals with CD4 Counts of 200-500/mm^3." Upjohn, project period 3/94-12/96.
Principal Investigator: "A Repeat Dose Safety and Efficacy Study of HIV-IT (V) in HIV-I Infected Subjects with > 100 CD4+ T Cells and no AIDS Defining Symptoms." Viagene, project period, 1/95-1/97.
Principal Investigator: "A Master Protocol to Evaluate the Safety and Efficacy of Multi-Drug Combination Antiretroviral Therapy for the Treatment of HIV Infection," Paraxel International, project period 3/95-6/96.
Principal Investigator: "Optional, Open Lavel, Extended Use Delavirdine Mesylate Treatment in Triple Combination for HIV-1+ Patients Who Participated in Other Delavirdine Mesylate Protocols". Upjohn, 10/95-10/97
Principal Investigator: "A Multicenter, double-blind, Phase III, Adjuvant-Controlled Study of the Effect of 40 Units of HIV-I Immunogen, 10 Units of HIV-1 Immunogen, and IFA Alone Every Three Months on AIDS Free Survival in Subjects with HIV Infection and CD4 Lymphocytes Between 300 and 549 Cells/æL Regardless of Concomitant HIV Therapies." Immune Response corporation.